Biointellisense

Wearable remote patient monitoring with analytics

Biointellisense

Wearable remote patient monitoring with analytics

Overview

BioIntelliSense offers remote patient monitoring through its BioButton wearable that continuously collects medical-grade vital signs for at-home use, with data fed to analytics for early-warning insights. Customers are hospitals, health systems, providers, and payors in the U.S. and select global markets, who buy the devices and analytics services to guide care and reduce hospital stays and emergencies. It differentiates itself by combining ease of use, comfort, and a cost-effective, continuous monitoring approach along with strategic healthcare partnerships (e.g., Ardent Health Services) and industry recognition. Its goal is to improve patient outcomes and lower healthcare costs by enabling proactive, at-home monitoring.

Work here?Claim your company

About Biointellisense

Simplify's Rating

Why Biointellisense is rated

C+

Rated B on Competitive Edge

Rated B on Growth Potential

Rated D+ on Differentiation

Industries

Data & AnalyticsHealthcare

Company Size

51-200

Company Stage

Series B

Total Funding

$82M

Headquarters

Golden, CO

Founded

2018

Get referred to Biointellisense

See people who can refer or advise you

Simplify's take

What believers are saying

February 2026 Houston Methodist data showed 27% lower relative mortality after ICU transfer.
February 2026 telemetry-overuse messaging targets hospital staffing shortages and budget pressure immediately.
The 2026 Hicuity Health partnership expands BioButton into hospital-at-home and post-discharge workflows.

What critics are saying

BioIntelliSense depends on large-system conversions; losing Houston Methodist or Ardent would crush revenue concentration.
iRhythm's 2024 exclusive license and Vital Connect pursuit intensify IP and channel competition by 2026.
No 2026 funding announcement surfaced; prolonged commercialization burn risks an existential cash squeeze.

What makes Biointellisense unique

BioButton monitors hospital patients continuously, with FDA-cleared multi-parameter wearables and BioDashboard.
Houston Methodist scaled BioButton across 2,653 non-ICU beds by April 2024, proving operational depth.
BioIntelliSense pairs hardware, analytics, and virtual monitoring through Hicuity Health and Medtronic partnerships.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$82M

Above

Industry Average

Funded Over

3 Rounds

Series B funding is typically for startups that have proven their business model and need more funding to expand rapidly—often by entering new markets or adding more products. Investors are usually venture capital firms that specialize in later-stage investments.

Series B Funding Comparison

Above Average

Industry standards

Ind Avg. $35M

$45M

$65M

$100M

Benefits

Health Insurance
Dental Insurance
Vision Insurance
HSA and Flexible Spending Accounts
Safe Harbor 401(k) Plan with 3% Employer Contribution with immediate vesting
Flexible Vacation Plans
Sick Leave
11 Company Holidays
Home Office Benefits Stipend

Growth & Insights and Company News

6 month growth

-1%

1 year growth

2 year growth

Castle Placement

Jan 8th, 2026

Top 10 Healthcare Devices and Supplies Capital Raises and Investors in the U.S. - November 16th to December 31st, 2025

Top 10 Healthcare Devices and Supplies capital raises and investors in the U.S. - november 16th to december 31st, 2025. Several interesting transactions closed in the Healthcare Devices and Supplies sector over the past month. If you would like more info or would like to discuss the capital raising market for your company, please contact me. * Positron, medical technology company that engages in the development, manufacturing, and sales of PET and PET-CT molecular imaging systems for nuclear medicine providers across North America, received $2 million of development capital from investors. * TELA Bio, commercial-stage medical technology that provides innovative soft-tissue reconstruction solutions and optimizes clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy, received $4.65 million of development capital from EW Healthcare Partners and Nantahala Capital Management. * Alerje, health technology solution for individuals with severe food allergies, was acquired by SemPresto. * Applied Tissue Technologies, wound care technologies that offer treatment of common acute and chronic wounds, was acquired by New Horizon Medical Solutions. * BioIntelliSense, remote patient monitoring device that enhances healthcare delivery, raised $58.05 million of venture funding. * eLux Medical, fat removal technology that disrupts the cosmetic surgery market, raised $11.28 million through a combination of Series B and Series B-1 venture funding from investors, putting the company's pre-money valuation at $12 million. * Entirety Biomedical, high-performance absorbable metal implants that improve the quality of life with advanced bioabsorbable implant technology, raised $1.2 million of venture funding in a deal led by NuFund Venture Group, putting the company's pre-money valuation at $8.8 million. * OrthoPreserve, meniscus implant device that replaces the damaged meniscus to relieve pain, restore mobility, and prevent the accelerated arthritis development that normally accompanies a meniscectomy, raised $157,000 of venture funding in the form of convertible debt financing from investors. * RedDrop Dx, device that allows blood collection to be done quickly, painlessly, and without a trained professional, raised $7 million of seed funding in a deal led by Phase Three Product Development, Stout Street Capital and Innosphere Ventures Fund. * TYBR Health, collagen-based resorbable hydrogel that protects healing tendons and ligaments and support recovery after surgery, raised $7.14 million through a combination of Seed Prime-1 and Seed Prime-2 funding from Johnson & Johnson Innovation - JLABS, Texas Medical Center and VentureSouq, putting the company's pre-money valuation at $9.66 million. Tamara williams. Managing director. Please contact me if you have any questions or would like to discuss your capital raise:

HIT Consultant

Feb 17th, 2025

AI-Powered Monitoring Meets 24/7 Virtual Care: BioIntelliSense and Hicuity Health Collaboration

- BioIntelliSense's FDA-cleared BioButton(R) wearable and BioDashboard(TM) clinical intelligence system will integrate with Hicuity Health's 24/7 virtual patient monitoring services.

HIT Consultant

Feb 17th, 2025

Ai-Powered Monitoring Meets 24/7 Virtual Care: Biointellisense And Hicuity Health Collaboration

What You Should Know:– BioIntelliSense, a leader in continuous health monitoring and clinical intelligence, and Hicuity Health, a leading provider of tech-enabled virtual care services, today announced a strategic partnership to offer fully managed, end-to-end continuous patient monitoring to hospitals and health systems.– This partnership addresses critical infrastructure and staffing challenges faced by hospitals and health systems, empowering them to deploy proven, scalable monitoring solutions for in-hospital care, hospital-at-home programs, post-hospital discharge and chronic remote care management.BioIntelliSense and Hicuity Health Partner to Enhance Continuous Patient MonitoringBioIntelliSense is transforming continuous health monitoring and clinical intelligence for virtual care and remote patient monitoring (RPM) across in-hospital and home settings. Its medical-grade Data-as-a-Service (DaaS) platform seamlessly captures multiparameter vital signs and physiological biometrics, offering an effortless user experience. The FDA-cleared BioButton® wearable, BioHub® gateways, BioMobile™ applications, BioCloud™ data services, and BioDashboard™ clinical intelligence system together create a scalable, reliable solution for continuous patient monitoring. AI-driven analytics provide clinicians with high-resolution patient trends and data-driven insights, enabling improved and safer care.Strategic Partnership with Hicuity Health· BioIntelliSense’s FDA-cleared BioButton® wearable and BioDashboard™ clinical intelligence system will integrate with Hicuity Health’s 24/7 virtual patient monitoring services.· This integration provides nurses and clinicians with actionable health insights and improved workflow efficiencies.· Hicuity Health’s services, delivering over 11 million hours of patient monitoring annually, reduce workforce burden and enhance high-acuity patient care.Advancing Scalable Continuous Care· “The combination of BioIntelliSense’s award-winning, medical-grade solution with Hicuity Health’s expertise ensures that health systems of all sizes can deploy and scale continuous care programs efficiently,” said James Mault, MD, CEO and Founder of BioIntelliSense.· The partnership addresses staffing challenges in health systems by providing a comprehensive, technology-enabled solution that enables earlier interventions, improves patient outcomes, and optimizes clinical resource utilization.Enhanced Virtual Care Capabilities· The rechargeable, wireless BioButton® wearable continuously and passively monitors patient vital signs and biometrics, automating 1,440 measurements per patient per day.· The BioDashboard clinical intelligence engine utilizes algorithmic-based analytics to track vital sign trends, securely monitored by Hicuity Health.· Hicuity Health’s clinical teams follow predefined workflows and escalation protocols in collaboration with health systems to ensure timely interventions and better patient outcomes.This collaboration offers hospitals and health systems an effective solution to initiate or expand their virtual care programs, enhancing efficiency, scalability, and patient care quality

TipRanks

Sep 4th, 2024

iRhythm signs exclusive license agreement with BioIntelliSense

iRhythm Technologies announced that the company has signed an exclusive license agreement with BioIntelliSense, a continuous health monitoring and clinical intelligence company, to develop and commercialize certain patented technology assets within ambulatory cardiac monitoring, ACM.

StreetInsider

Sep 4th, 2024

iRhythm Technologies (IRTC) Enters License Agreement with BioIntelliSense for Multiparameter Sensor Technology to be Used in Ambulatory Cardiac Monitoring

iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company has signed an exclusive license agreement with BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company, to develop and commercialize certain patented technology assets within ambulatory cardiac monitoring (ACM).

Recently Posted Jobs